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Abstract
Methicillin-Resistant Staphylococcus aureus (MRSA) poses a serious threat to worldwide health.
Historically, MRSA clones have strictly been associated with hospital settings and most hospital-
associated MRSA (HA-MRSA) disease resulted from a limited number of virulent clones.
Recently, MRSA has spread into the community causing disease in otherwise healthy people with
no discernible contact with healthcare environments. These community-associated (CA-MRSA)
are phylogenetically distinct from traditional HA-MRSA clones and CA-MRSA strains seem to
exhibit hyper virulence and more efficient host:host transmission. Consequently, CA-MRSA
clones belonging to the USA300 lineage have become dominant sources of MRSA infections in
North America. The rise of this successful USA300 lineage represents an important step in the
evolution of emerging pathogens and a great deal of effort has been exerted to understand how
these clones evolved. Here we review much of the recent literature aimed at illuminating the
source of USA300 success and broadly categorize these findings into three main categories: newly
acquired virulence genes, altered expression of common virulence determinants and alterations in
protein sequence that increase fitness. We argue that none of these evolutionary events alone
account for the success of USA300, but rather their combination may be responsible for the rise
and spread of CA-MRSA.
Multidrug-resistance in Staphylococcus aureus: the rise of MRSA
The Gram-positive pathogen Staphylococcus aureus remains one of the most problematic
and costly sources of bacterial infection worldwide1. Disease typically presents as mild skin/
soft tissue infections but can also be the source of more serious bacteremia, endocarditis,
osteomyelitis and necrotizing pneumonia2. S. aureus asymptomatically colonizes the skin,
and more commonly, the anterior nasal passages of healthy people3. Nasal colonization is
the most significant predictor of invasive disease, however, in some studies, nearly half of
patients carrying S. aureus are strictly colonized extranasally4. Thus, estimates of S. aureus
carriage at ~25% of the human population may be an underestimate of true colonization
levels. Given the near ubiquity of S. aureus among the human population combined with its
virulence potential, it is no wonder this organism has been recognized as a significant
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healthcare burden for over a century. S. aureus was first described by Alexander Ogston in
1881 as the sole microorganism within the fluid drained from a severe knee abscess5. Then,
he noted that “once established the micrococci are hard to kill…” underscoring the
recalcitrant nature of S. aureus towards antiseptic treatment6. During this time, Joseph
Lister’s influence on surgical procedures through the implementation of carbolic acid
(phenol) to sterilize wounds and instruments, had greatly reduced the occurrence of post-
operative infections7. However, it was subsequently shown that S. aureus was inherently
resistant to phenol explaining its association with surgical infections despite good “sterile
technique”8. Thus, S. aureus was recognized as an important hospital associated pathogen
over 130 years ago in the pre-antibiotic era and little has changed to this day.
Perhaps because of its intimate association with hospitals and patients, S. aureus has always
been among the first bacterial species reported to develop resistance to new antimicrobials,
from sulfonamide-resistance in the early 1940s9 to the identification of penicillinase in
194410 just months after US penicillin production reached full scale. Interestingly, these
progenitor β-lactamase positive S. aureus clones were isolated from patients that had not
even been treated with penicillin. Nonetheless, Penicillin-Resistant S. aureus (PRSA) was
here to stay, and became pandemic in hospitals during the late 1950s and early 1960s11.
Subsequently, a penicillinase-resistant β-lactam derivative, methicillin (Celbenin, Beecham
Pharmaceuticals), was approved for use in the US in 1959. Less than two years later, the
first report of methicillin-resistant S. aureus (MRSA) was published documenting the
isolation of MRSA clones from a patient and hospital staff in the UK, again none of which
were treated with methicillin12. It was immediately recognized that methicillin-resistance
was mechanistically different than penicillin-resistance in that the MRSA phenotype did not
involve direct inactivation of the drug. Rather, resistance was mediated through the
acquisition of an alternative penicillin-binding protein (PBP2a) with lowered affinity for β-
lactam antibiotics. Within 20 years after the first discovery of MRSA, it became a leading
cause of hospital-acquired infections13. Currently, it can still be responsible for nearly 60%
of skin/soft-tissue infections presenting to US emergency rooms14.
The methicillin-resistance determining PBP2a is encoded by mecA harbored on a mobile
genetic element, Staphylococcal Cassette Chromsome (SCCmec). A nearly identical
homologue, now thought to be the ancestral mecA, was recently discovered in
Staphylococcus fleuretti, an animal colonizing staphylococcal species15. Unlike a previously
identified mecA homologue in Staphylococcus sciuri that does not confer methicillin-
resistance16, S. fleuretti is fully resistant to β-lactam antibiotics. Interestingly, the S. fleuretti
mecA homologue is not found on a mobile SCC, but rather in the core chromosome between
the mevalonate biosynthetic and xylose utilization operons, explaining the presence of mva
and xyl gene fragments in some S. aureus SCCmec elements15. These mobile islands have
diversified considerably over the 50-year history of MRSA such that there are currently
eight distinct SCCmec types circulating among S. aureus as well as some species of
coagulase negative staphylococci17. SCCmec elements can vary greatly in size and
composition with the largest (SCCmec type II) spanning 52 kb and additionally encoding
erythromycin-, spectinomycin- and tobramycin-resistance determinants18. Depending on the
particular SCCmec type, these mobile islands peppered with IS elements, transposons and
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integrated plasmids, can confer multidrug-resistance determinants that significantly diminish
treatment options in a clinical setting. Thus, in addition to methicillin resistance, MRSA
isolates have evolved multidrug-resistance leading to what the popular press refers to as an
emerging superbug19.
Paradigm-shift: The rise of CA-MRSA
After 1961, MRSA spread worldwide causing significant morbidity and mortality almost
entirely as hospital-acquired infections. Advances in molecular epidemiology allowed for in
depth analyses of MRSA spread and expansion at the evolutionary level. For instance, spa-
typing (polymorphisms in Protein A coding sequence) and SCCmec-typing discriminated
unrelated clones and identified clusters of related MRSA lineages responsible for
disease20,21. Multi-Locus Sequence Typing (MLST) involves the sequencing of fragments
from seven “housekeeping” genes (arcC, aroE, glpF, gmk, pta, tpi and yqiL) yielding unique
sequence types (STs)22. STs sharing identity at the majority of these loci are grouped into
Clonal Complexes (CCs) encompassing related lineages of MRSA23. Another highly-
discriminatory approach that can identify genomic rearrangements and insertions/deletions
is Pulsed-Field Gel Electrophoresis (PFGE) whereby SmaI digested chromosomal DNA is
separated and similarities in banding patterns reflect relatedness among lineages24,25. This
allows for the classification of S. aureus strains into the now familiar PFGE-types USA100–
1200. Employing these epidemiological approaches,researchers appreciated that most
MRSA disease worldwide (nearly 70% of reported infections) was caused by five major
CCs: CC5, CC8, CC22, CC30 and CC4524,26 (Figure 1). CC5 includes clones belonging to
the USA100 PFGE-type (e.g. SCCmec-II New York/Japan clone) the most common source
of US hospital acquired MRSA as well as USA800 (SCCmec-IV Pediatric clone). CC8
includes the archaic, or original MRSA clones as well as the related Iberian clone, the
SCCmec-III Brazilian/Hungarian clone and the SCCmec-IV USA500 clones. CC22 includes
the EMRSA-15 clones that dominated hospital infections in the UK during the 1990s along
with strains from CC30 encompassing EMRSA-16 as well as the USA200 PFGE type.
Finally, CC45 consists of clones belonging to USA600 PFGE type (e.g. Berlin clone) that
caused widespread MRSA hospital infections in northern Europe. In essence, after 30 years
of investigation, the scientific community began to understand the population structure of
the MRSA clones responsible for the majority of hospital-acquired disease. The source of
high-virulence potential inherent to these five CCs was never fully appreciated before
everything we knew about MRSA epidemiology changed at the turn of the century.
Initially reported in 1993, patients without any contact with healthcare settings contracted
invasive MRSA infections in Kimberly Australia, a region in the northern part of Western
Australia27. It was later discovered that simultaneously, strains related to these “community-
acquired” MRSA (CA-MRSA) clones were causing serious and fatal respiratory infections
in Chicago, again in patients without direct contact with hospital environments28. Prior to
these reports, MRSA infections were exclusively associated with healthcare settings. These
new clones belong to CC1 (USA400 PFGE type), a clonal complex unrelated to the five
traditional Hospital-Associated MRSA (HA-MRSA) complexes28. CC1 clones spread
quickly through Australia, the mid- and northwestern United States as well as Canada and
Alaska where they still cause significant CA-MRSA disease28–32. Recent studies show that
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USA400 can account for over 98% of MRSA infections in northern Canada33 and has been
implicated in isolated MRSA disease in southern Europe34,35. However, about 10 years ago
a new source of CA-MRSA arose from one of the “traditional” virulent clonal complexes,
CC8. Descending from a USA500 clone through acquisition of various mobile genetic
elements (MGEs)26,36, USA300 became the dominant CA-MRSA clone in US14,37,38,
effectively replacing USA400 clones in most regions39,40, and has also been isolated from
patients in Canada and Mexico41,42. The explosion of USA300 CA-MRSA across North
America resulted from a very recent clonal expansion of a successful CA-MRSA clone as
demonstrated by very low sequence divergence among geographically distinct USA300
isolates43.
Given the occurrence of multiple CA-MRSA clones in the population, a formal definition
was put forth by the Centers for Disease Control and Prevention for CA-MRSA disease as
that which is contracted within 48 hours of hospital admission by patients not having
recently undergone surgery, hemodialysis, prolonged hospitalization, catheterization or
MRSA colonization44. Currently in the US, MRSA disease fitting these criteria is almost
always caused by USA300 clones, followed by USA400 and occasionally USA1000 and
USA110014. To complicate matters further, USA300 clones have recently been implicated
in causing significant HA-MRSA disease38,45–47, blurring the lines between the two disease
onset environments38,45–47. In some studies, USA300 accounted for at least half of hospital
acquired MRSA infections38,46. Thus, USA300 represents a highly successful S. aureus
clone that emerged in the community and quickly spread throughout the North American
continent to become the leading cause of MRSA infection even in healthcare settings. For
now, USA300 seems to be primarily limited to North America, while in Europe, South
America and Asia CA-MRSA disease is dominated by divergent clones unrelated to CC8
(e.g. ST30, ST80 and ST59)48. Given the rapid and efficient transmissibility of USA300 in
North America49, it remains to be seen whether these clones will become the dominant
source of MRSA disease worldwide.
USA300 Virulence
Animal models of S. aureus infection have repeatedly demonstrated the hypervirulence
associated with USA300 compared to other MRSA strains36,50–52. USA300 strains exhibited
enhanced production of dermonecrotic lesions in skin abscess models when compared to
HA-MRSA clones36,50,51 and USA300 was more lethal in a rat model of pneumonia
compared with a USA400 isolate52. Furthermore, USA300 strains were more lethal in septic
infections compared to archaic and Iberian clones as well as ST239 clones (Brazilian
clones)36. When compared to other CA-MRSA clones, USA300 isolates generally exhibit
increased virulence with the exception of ST80 and USA1000, which also possess enhanced
virulence51. In contrast, nearly every clone of HA-MRSA tested was significantly less
virulent than USA300 with the only exception being USA500 HA-MRSA36,51. This is of
particular interest in that USA300 clones descended from USA500 via the acquisition of a
prophage containing Panton-Valentine Leukotoxin (PVL), a mobile Arginine Catabolic
Mobile Element (ACME) and enterotoxins K and Q (see below)36. Thus, the source of
USA300 hypervirulence may have originally evolved in the HA-MRSA isolates belonging
to USA500. However, for unknown reasons, despite exhibiting hypervirulence in animal
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infection models, USA500 clones remain relegated to healthcare settings and do not cause
significant CA-MRSA disease. Whether CA-MRSA USA300 clones exhibit hypervirulence
in human disease has been difficult to directly discern, however, recent population based
clinical data are beginning to corroborate conclusions drawn from laboratory animal model
experiments.
In humans, USA300 S. aureus primarily causes skin infections of which, it can account for
up to 98% of all MRSA presenting as skin/soft tissue infections to US emergency rooms14.
In addition, USA300 can also cause more invasive disease such as bacteremia53,
endocarditis54 and necrotizing fasciitis55, a condition almost never associated with S.
aureus. In particular, pulmonary infections caused by USA300 S. aureus can lead to
aggressive and often fatal necrotizing pneumonia56–58. The populations most at risk for
contracting USA300 CA-MRSA are military personnel59, athletes60–62, prisoners63–65,
African Americans58,66, daycare attendees67,68 and men who have sex with men69. Patients
contracting CA-MRSA are, on average, younger than those with HA-MRSA and otherwise
generally healthy70,71. Furthermore, CA-MRSA is often associated with worse clinical
outcomes. For instance, USA300 infections were associated with increased in-hospital
mortality and a higher occurrence of severe sepsis than HA-MRSA infections66,72. USA300-
related strains were also more prone to spread from the initial infection site and caused more
severe infections than HA-MRSA in patients suffering from pneumonia with pulmonary
emboli73,74. However, other reports describe better clinical outcomes associated with
USA300 infections45,75. Although some studies that reported more positive clinical
outcomes with CA-MRSA also described hypervirulent CA-MRSA trends, such as increased
risk of being admitted into intensive care, that merely lack full statistical significance (OR =
1.8, p = 0.09)46. Additionally, effective treatment, which is easier to achieve when treating
CA-MRSA infections given their inherent susceptibility to clindamycin, tetracyclines,
rifampicin and trimethoprim/sulfonamide, can reduce the severity of CA-MRSA disease
outcomes in population-based studies76. Unfortunately, this trend of increased antibiotic
susceptibility may be diminishing as new reports show increased antibiotic resistance among
USA300 isolates, possibly through direct acquisition of resistance determinants from
multidrug-resistant HA-MRSA strains77. Thus, the future clinical outlook appears grim with
respect to USA300 infections given their increased prevalence in both hospital- and
community-acquired infections, their propensity to acquire new antibiotic resistance
determinants and the steady decline in positive clinical outcomes associated with USA300
infections.
Genetic Determinants Contributing to USA300 Success
Given the recent impact of USA300 on human health, significant research effort has been
exerted to elucidate the source of USA300 success. Here we review these findings and
broadly categorize them into three main classes: 1. Newly acquired genes that promote
virulence and/or fitness, 2. Altered regulation of core genes resulting in elevated virulence
and/or fitness and 3. Non-synonomous mutations in core genes that enhance virulence
and/or fitness.
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Many different lineages of CA-MRSA (USA400, USA1000, and USA1100) cause outbreaks
and invasive infections, but in North America, none are as prevalent as epidemic USA300.
These clones have acquired many genes in the form of Mobile Genetic Elements (MGEs)
that may confer a selective advantage over other CA-MRSA strains. Several groups have
investigated many of these MGEs with the goal of elucidating factors (if any) that have
contributed to the overwhelming success of USA300.
Enterotoxins K and Q
USA300 CA-MRSA isolates contain genes encoding enterotoxins K and Q (sek2 and seq2)
in a unique pathogenicity island SaPI5 78. Sek2 and Seq2 are thought to contribute to
pathogenesis by stimulating T-cells through binding of the Vβ chain of αβ T-cell receptors.
Sek2 and Seq2 share 98% amino acid homology with enterotoxins (Sek and Seq) found on
SaPI3 in S. aurueus COL an archaic HA-MRSA clone belonging to ST250 that is less
virulent than CA-MRSA isolates79. USA400 isolates (e.g. MW2) harbor νSA3, a
pathogenicity island that shares similarity to SaPI3 of COL and SaPI5 of USA300, however,
νSA3 does not contain the genes for Sek or Seq78. Thus, the acquisition of these toxins by
USA300 and not US400 may potentially explain the differences in pathogenicity although
direct demonstration of this has not been reported.
SCCmecIVa
The mecA gene encodes a penicillin-binding protein and is located on a mobile genetic
element known as the Staphylococcal Cassette Chromosome mec (SCCmec). There are
currently eight recognized SCCmec types (I VIII). SCCmec types I, II and III contain
additional drug resistance determinants, whereas types IV, V, VI, and VII cause resistance
only to β-lactams80. Initial sequence comparisons show that both USA400 and USA300
strains contain a nearly identical SSCmecIVa78,81. As it turns out, SCCmecIV is the most
common form of SCCmec found across divergent S. aureus lineages in addition to ST8
(USA300) including ST1 (USA400), ST80, ST72 (USA700) and ST8 (USA500)82,83. It has
been shown that SSCmecIV does not impose a fitness cost in vitro or in vivo, whereas
acquisition of the SSCmec types I, II and III resulted in decreased in vitro growth rates84–86.
Thus, it is thought that harboring SSCmecIV as opposed to other SCCmec types imparts CA-
MRSA with an advantage in its ability to cause infection in healthy individuals. However,
though SSCmecIV may provide a selective advantage to CA-MRSA over other SCCmec
types, the fact that nearly all CA-MRSA isolates contain SSCmecIVa suggests that it is not a
major contributing factor to the dominance of USA300 among CA-MRSA isolates.
Panton-Valentine Leukocidin (PVL)
The Panton-Valentine leukocidin (PVL) is a bicomponent pore-forming toxin that induces
necrosis and apoptosis in leukocytes87. PVL is encoded by the genes lukS-PV and lukF-PV
located on the prophage ϕSA2 pvl78. This phage is highly associated with CA-MRSA clones
in that nearly all USA300, USA400 and USA1100 clinical isolates are positive for PVL as
are many USA1000 strains88,89. Furthermore, epidemiological and clinical reports indicate a
strong correlation between PVL production and severe skin/soft tissue infections, as well as
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necrotizing pneumonia and fasciitis, suggesting PVL may be a major contributor to the
virulence of CA-MRSA90–92. Moreover, PVL can be directly detected in human skin
abscesses at levels known to result in rapid neutrophil lysis93,94. Thus, PVL is significantly
correlated with invasive CA-MRSA disease, however, recent clinical studies demonstrate
that CA-MRSA strains lacking PVL can still cause disease outbreaks95–97.
Until recently, demonstrating a direct role for PVL in model disease has proven difficult.
This likely stems from the host specificity of PVL in that it is rapidly leukocidal for rabbit
and human neutrophils, but much less active against murine, rat or simian PMNs98.
Consequently, a virulence effect of PVL in murine or rat pneumonia, sepsis and skin
infection models has never been reproducibly defined99–104. Moreover, there was no
demonstrable role for PVL in a pneumonia model involving nonhuman primates105. In
contrast, using PVL susceptible rabbit models, isogenic USA300 strains lacking PVL were
less virulent in pneumonia, osteomyelitis and skin abscess models106–109. However, the
attenuation of mutants lacking PVL in rabbit skin lesions was not nearly as striking as a
mutant lacking α-hemolysin or phenol-soluble modulin production underscoring the
contributory nature of PVL towards S. aureus pathogenesis108,110. Furthermore, the nearly
ubiquitous presence of PVL among CA-MRSA isolates clearly suggests that this toxin
cannot explain the particular success of the USA300 lineage.
Arginine Catabolic Mobile Element (ACME)
Of all the genetic elements acquired by CA-MRSA isolates, only the arginine catabolic
mobile element (ACME) is completely unique to USA30078. The type 1.02 ACME carried
by USA300 is juxtaposed to the SCCmecIV island and was acquired from S. epidermidis
through horizontal gene transfer via a mechanism likely involving the SCCmec-related
CcrAB recombinases78,84,111. The physical linkage of ACME with SCCmecIVa is mirrored
by an epidemiological linkage in that nearly all USA300 strains harboring SCCmecIVa also
carry ACME, while USA300 clones with other SCCmec islands, with rare exceptions, do
not83,112. The ACME of USA300 contains a complete arginine deaminase (arc) system that
converts L-arginine to L-ornithine for both ATP and ammonia production. The island also
encodes a putative oligopeptide permease, a zinc-containing alcohol dehydrogenase, and a
spermine/spermidine acetlytransferase (SpeG) as well as several hypothetical proteins78.
While a role for ACME in USA300 virulence was demonstrated in a rabbit sepsis model84,
no effect of ACME was observed in murine pneumonia or skin abscess models113. Thus, it
has been proposed that ACME aids primarily in USA300 colonization, in part, through the
Arc mediated ammonification of the acidic skin environment, though this has never been
experimentally verified84,114.
We have additionally observed a peculiar phenotype in S. aureus suggestive of a selective
advantage afforded by the ACME cassette. Polyamines, including spermine, spermidine and
putrescine are a group of polycationic compounds reportedly synthesized from L-arginine by
all living organisms. Not only does S. aureus lack the ability to synthesize polyamines de
novo, but spermine and spermidine are bactericidal to this organism at levels found within
mammalian tissue115,116. Polyamine-sensitivity was apparent in all tested strains except
those belonging to USA300, and in these isolates polyamine-resistance was dependent on
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speG encoding a spermine/spermidine aceytltrasferase harbored on ACME. Could speG
provide USA300 with a selective advantage by nullifying the staphylocidal effects of host
polyamines? While no direct measure of host polyamine levels during S. aureus infections
have been reported, several indirect lines of evidence may suggest that polyamines do affect
the outcome of staphylococcal disease and/or colonization.
Upon wounding, the host response in the skin is proinflammatory and dominated by
cytokines such as IL-1, INF-γ and TNF- α117. The resulting inflammation is mediated,
among other effectors, by the production of reactive oxygen and nitrogen species, the latter
of which, nitric oxide (NO·) is synthesized from L-arginine by the inducible NO·-synthase
(iNOS, Figure 2). This enzyme competes for available L-arginine with host enzymes such as
Arginase-1 (Figure 2) as well as with arginine-auxotrophic S. aureus118. Once tissue damage
signals resulting from the primary inflammation outweigh pathogen-associated signals, the
host response shifts away from proinflammatory mediators and initiates the profibrotic
response117. This phase is dependent on the production of TH2-like anti-inflammatory
cytokines such as IL-4, IL-10, IL-13 and TGFβ and results in induction of host fibrotic
response involving Arginase-1 expression. At this stage the L-ornithine produced by
Arginase-1 can be converted to staphylocidal polyamines that will additionally promote
fibroblast proliferation, collagen deposition and inhibition of inflammation (e.g. blocking
iNOS translation)119. It therefore may be during this TH2-dominant fibrotic phase that host
polyamines exert their effects on invading S. aureus thereby selecting for ACME encoded
SpeG. Indeed, inhibiting IL-4 signaling in mice increased organism burdens during S.
aureus sepsis while INF-γ -/- mice (lacking robust inflammatory wound response) survived
better than WT mice120. Thus, TH2-dependent signaling, as opposed to an inflammatory
TH1 response, proved critical to the host’s ability to control S. aureus infections. Recently,
protection against chronic implant infections was also highly dependent on an effective TH2/
Treg response121. Furthermore, polymorphisms in the human IL-4 gene associated with
reduced IL-4 production are significantly linked with increased S. aureus colonization122.
These data are consistent with the TH2 anti-inflammatory fibrotic response as being critical
for controlling S. aureus infection. Whether this is directly due to the induction of
polyamine synthesis has yet to be reported, but the acquisition of speG-encoding ACME
would counter increased spermine levels in fibrotic tissue perhaps explaining the association
of USA300 CA-MRSA with severe skin/soft tissue infections.
How do we reconcile a significant role for SpeG in S. aureus pathogenesis with the lack of a
strong ACME phenotype in most model infections84,113? One explanation could be that the
observed increase in α-hemolysin and Protein A expression upon ACME inactivation in
USA300 could overcompensate for the resulting polyamine-sensitivity84. Another
possibility is that the Arc operon on ACME actually drives excess polyamine production
necessitating SpeG-mediated spermine detoxification. The Arc operon consists of genes that
convert L-arginine to L-ornithine and CO2 while producing ATP and ammonia. The
resulting L-ornithine is exchanged for extracellular L-arginine by the L-arginine/L-ornithine
antiporter ArcD effectively converting extracellular L-arginine to L-ornithine. Thus, the Arc
operon could skew the flux of host L-arginine away from iNOS towards polyamine
synthesis rendering speG essential (Figure 2). Deleting all of ACME might allow the host to
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partition available L-arginine towards NO·-production, an immune effector that S. aureus is
known to effectively resist123–125. This is consistent with the presence of speG on ACME
islands that harbor the auxiliary arc gene cluster (Figure 2). While this hypothesis could
explain the modularity of ACME that results in ΔspeG attenuation, it has several aspects that
require experimental attention. First, all strains of S. aureus already encode an Arc operon
on the core chromosome that could also result in excess host polyamine synthesis, yet SpeG
is only associated with ACME-positive USA300 S. aureus. This could be explained by the
fact that the chromosomal Arc operon is only expressed under conditions of low oxygen and
low glucose and little is known about ACME Arc expression in S. aureus126. Second, a
dominant MRSA clone of ST22 lineage in Irish hospitals harbors an ACME island with an
arc gene cluster but appears to lack a speG homologue112. Another issue is that significant
CA-MRSA disease in Latin America is caused by USA300 clones that lack ACME127.
Thus, ACME may contribute to colonization and virulence, but it cannot fully explain the
predominance of USA300 in CA-MRSA disease in North America.
Enhanced Virulence Gene Expression
S. aureus elaborates a wide variety of toxins and proteases that have proven critical for
efficient dissemination, inflammation and disease progression128–130. For instance, α-toxin
or α-hemolysin (Hla) is a potent heptameric pore-forming toxin known to be critical for
virulence in nearly every tested disease model from skin lesions and endocarditis to murine
mastitis131–133. Upon interacting with susceptible cells, which include leukocytes,
keratinocytes, platelets and endothelial cells, it forms a 100 Å deep pore in the plasma
membrane resulting in rapid cell lysis134,135. Recently, a number of reports have shown that
Hla expression is highly elevated in USA300 clones compared with other S. aureus
isolates36,50–52. Moreover, deletion of hla abrogates USA300 virulence in murine and rabbit
skin lesion models as well as pneumonia43,100,136. However, it should be noted that hla
mutants in almost any S. aureus background are attenuated133,137–140, thus the loss of
virulence in USA300 hla mutants is consistent with α-toxin in general being a critical
pathogenicity factor to S. aureus. δ-toxin (encoded by hld) and related α-type phenol-soluble
modulins (αPSMs) are amphipathic α-helical peptides with potent leukocidal and
chemotactic properties141. They have been shown to be overproduced by CA-MRSA clones
with respect to most HA-MRSA isolates36,51,141. Their abundant production is essential for
full virulence in murine and rabbit skin models of infection as well as murine sepsis108,141.
Interestingly, they have recently been shown to exert potent antimicrobial activity against
multiple Gram-positive bacterial species142. This property may prove critical for efficient
colonization of non-sterile sites such as skin and nasal passages, thereby providing CA-
MRSA with a selective advantage during transmission. Finally, S. aureus expresses a
number of secreted proteases that, while antagonistic to in vitro biofilm formation, likely
mediate the breakdown of host fibrotic tissue synthesized to confine S. aureus-containing
lesions thereby promoting bacterial dissemination and disease progression. As with α-toxin
and αPSMs, USA300 clones are also known to excrete proteases in excess, potentially
limiting the host’s ability to control minor skin and soft-tissue infections143. Thus, several
groups have consistently reported the robust expression of numerous virulence determinants
in USA300 compared with other clinical isolates. It has therefore been hypothesized that this
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over-production of toxins/proteases confers the selective advantage that explains the
overwhelming success of USA300 clones. If true, the regulatory mechanisms explaining
these virulence trait expression phenomena are poorly defined.
Agr Quorum Sensing System
S. aureus expresses a peptide-based quorum sensing system known as Agr for Accessory
Gene Regulator129,144. Signaling is mediated through a peptide form of AgrD (processed by
the combined activity of the AgrB endopeptidase and a type I signal peptidase, SpsB145) that
stimulates the two-component system sensor kinase, AgrC. The resulting activation of the
response regulator AgrA leads to induction of the agrBDCA operon as well as the
divergently transcribed RNAIII. While RNAIII encodes δ-toxin, the RNA molecule itself
mediates a significant proportion of Agr regulation by affecting the expression of α-
toxin146, protein A147, repressor of toxins (Rot)148 and others149. Active AgrA is also
known to directly control the expression of other virulence determinants including the
PSMs150. Thus, the reported overproduction of Hla, Hld and PSMs in USA300 clones may
be explained by a hyperactive Agr system in these clones. Indeed, the RNAIII molecule was
shown to be expressed to a higher level in USA300 clones than in other S. aureus isolates
explaining the overabundance of δ-hemolysin production51,52. Additionally, the overactive
USA300 Agr system was the source of excess PSM and protease production associated with
these clones and was partially responsible for excessive Hla expression50. Consistent with
these data, Δagr mutants in USA300 are highly attenuated in murine sepsis, pneumonia and
skin abscess models50,108,151. Though, given the importance of Agr in virulence gene
regulation, it is not surprising that mutants exhibit such attenuation. Moreover,
overproduction of PSMs was reported for USA400 CA-MRSA clones implying that the
greater success of USA300 cannot be fully attributed to overactive Agr51,141. In fact,
USA500 clones, thought to be ancestral to USA300 also exhibit phenotypes with
hyperactive Agr as well as being highly virulent in murine model infections36,51. Thus, the
high virulence potential of USA300, including high Agr-activity, likely evolved in the HA-
MRSA clones belonging to USA500. Still, Δagr mutants of USA300 are highly attenuated
and exhibit no increased virulence relative to non-USA300 agr mutants underscoring its
importance in the evolution of USA30050.
SaeR Two-Component System
The S. aureus exoprotein expression (Sae) locus contains four genes, saePQRS the latter of
which comprise a two-component regulatory system152–154. The response regulator/sensor
kinase genes (saeRS) are preceded by genes encoding a membrane protein (SaeQ) and a
lipoprotein (SaeP) of unknown function. All four genes are cotranscribed from a promoter
that is strongly induced by active SaeR155. A second promoter drives the expression of
saeRS alone and is modestly repressed by these regulatory gene products155. Activation of
the Sae system seems to involve sensing changes in the overall integrity of the cell envelope
and is highly stimulated by hydrogen peroxide and cationic peptides including α-
defensins155,156. Active SaeR promotes the induction of a number of virulence genes in S.
aureus through binding of a consensus sequence found upstream of promoters for hla, sbi,
efb, lukS-PVL, splA and saeP157. Additionally, expression of β-hemolysin, fibrinogen-
binding proteins, lactose catabolizing enzymes and the chromosomal arginine deiminase
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operon are all highly affected by Sae158. It has been shown that SaeRS expression is higher
in USA300 than in USA400 clones52,155_ENREF_52, which may be a result of overactive
Agr system (see above) since RNAIII is known to positively regulate Sae expression156.
Deletion of saeRS resulted in almost complete loss of Hla expression and a significant drop
in PVL levels as well151,157. Moreover, Δsae USA300 was attenuated in murine sepsis,
peritonitis, dermonecrosis and pneumonia models151,157–159. This was surprising given that
in USA400, Sae was only essential for sepsis and peritonitis and not for survival within skin
abscesses158,159. However, USA400 clones do not induce the same level of dermonecrosis
and do not express high levels of Hla as in USA300 infections51,52. Thus, it appears as
though some of the hypervirulence attributed to USA300 clones in skin/soft tissue infections
is likely due to Sae-mediated Hla overproduction. However, HA-MRSA USA500 clones
also exhibit severe dermonecrosis during skin infections and overproduce Hla and PSMs yet
have not disseminated as widely as USA300.
Source of overactive Agr
While it has not been directly tested, it is tempting to hypothesize that the overactive Agr
system inherent to USA300 results in excessive PSMs and Sae expression, the latter of
which leads to high Hla expression. However, the mechanism driving high Agr activity in
USA300 is not defined. Agr activity can be modulated through the actions of a number of
trans-acting regulators including SarA160, Stk1161, MgrA162, SigB143, CodY163, CcpA164,
Sar-family proteins other than SarA165–168, ArlRS169, Rsr161 and SrrAB170. Many of these
regulators are presumed to affect Agr expression indirectly, however some (CodY171,
SrrA172 and SarA173) have been shown to directly bind to the Agr locus. It is intriguing that
many of these regulators are involved in modulating metabolic adaptation to various
environments (CodY, CcpA, Rsr and SrrAB) given the apparent increase in fitness
associated with USA300174 (see below). Though any one of these or other unknown
regulatory systems may be responsible for enhanced Agr activity in USA300, therefore
investigations into strain-specific differences in activity among these regulators may prove
enlightening. For instance, SarA positively affects Agr expression160,175, and deletion of
sarA in USA300 lead to drastic reductions in Hla and PSM levels176,177. However, recently
it was demonstrated that the loss of cytolytic expoprotein expression in the ΔsarA mutant
was attributed to the resulting overproduction of extracellular proteases and not due to
altered exoprotein gene transcription177.
While trans-acting regulators may prove to be major influences on USA300 Agr activity,
cis-acting polymorphisms may also be involved. RNAIII transcripts among sequenced ST8
isolates are 100% conserved, but there is a single nucleotide polymorphism (SNP) 3 bp
upstream of a known AgrA binding site within the RNAIII promoter that is only found
among USA300 isolates. While this is the only SNP among ST8 and ST1 clones specific to
USA300, other sites of variation exist when compared to USA100 and USA200 promoter
sequences. SNPs in the Hla promoter were recently shown to drive its overexpression in
bovine isolates by modulating SarZ binding178. It remains to be determined whether SNPs in
the RNAIII promoter region of USA300 isolates affect expression leading to high Agr
activity. Regardless of the mechanism behind hyperactive toxin production in USA300, it is
important to remember that similar high-level expression is observed in the HA-MRSA
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progenitor clone, USA500. Thus, while the high virulence potentials of USA300 and
USA500 may result from overproduction of exoproteins, this phenomenon alone cannot
fully explain the enormous success of USA300 in human disease.
Non-synonymous Mutations in Core Genes
The evolutionary forces that drive diversification in S. aureus have been recently examined,
in part, due to the availability of more than 15 published S. aureus genome sequences. While
a significant level of divergence is achieved through acquisition of mobile genetic elements
(MGE), variability within the S. aureus core genome (~2000 orthologous genes shared
among most S. aureus strains) is primarily generated through mutation179,180. The most
common forms of mutation are single nucleotide polymorphisms (SNPs) or short insertion/
deletions (indels) that have been estimated to be ~15-fold more attributable to de novo
mutation than to recombination179. However, recent reports contend that the contribution of
homologous recombination to core diversity in S. aureus may be underestimated181.
Nevertheless, mutation is a significant driving force in S. aureus diversification allowing for
evolutionary classification of strains into ST types (see above)22. Most SNPs are within
coding regions reflecting the fact that ~80% of the core genome encodes protein182.
Synonymous SNPs, those that do not result in amino acid changes, by far outweigh amino
acid substituting non-synonymous SNPs in S. aureus183–186. This is likely because
nonsynonymous mutations are more often detrimental and are therefore subject to
evolutionary loss via purifying selection. Consequently, the relative ratio of nonsynonymous
to synonymous substitution rate (dN/dS) among staphylococci is generally less than 1. In
contrast, a recent report comparing the complete genome sequences of 10 newly isolated
USA300 clones with the published FPRF3757 USA300 sequence revealed an unusually high
ratio of nonsynonymous:synonymous SNPs (as high as 2.6:1, much higher than reported in
comparisons of non-USA300 S. aureus lineages)43. This discrepancy can be rationalized by
assuming a recent clonal expansion of the USA300 lineage such that new isolates still
harbor nonsynonymous SNPs that have not yet undergone purifying selection187. To be sure,
the unusually high dN/dS ratio of USA300 clones is inconsistent with evolutionary
convergence among distantly related clones, an event that would only be consistent with
normal to low dN/dS ratios if the converging progenitors were of sufficiently diverse
origins43.
It is important to note that overall low dN/dS ratios are not necessarily constant across all
functional gene families. For instance, while housekeeping and metabolic genes generally
exhibit low dN/dS ratios, genes encoding surface associated or secreted proteins can often
have elevated dN/dS ratios188,189. This is indicative of forward selective pressures driving
variability in these genes either to promote functional differences (e.g. an adhesin adapting
to a host receptor molecule) or immune avoidance through changes in antigenicity. Indeed,
comparisons among divergent S. aureus clones reveal higher dN/dS ratios for genes
encoding components of the cell envelope and secreted proteins than genes encoding
housekeeping or metabolic enzymes182,184,185. USA300 clones however seem to be an
exception to this rule. A recent comparison of genome sequences from USA200, USA300
and a distantly related S. aureus strain revealed high dN/dS ratios indicative of forward
selection in a large number of USA300 metabolic genes190. The largest subset of USA300
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genes predicted to be under positive selection (45%) were involved with metabolism
whereas only 7% encoded components of the cell envelope. This phenomenon cannot be
explained by the fact that metabolic genes make up a large proportion of the core genome
because this same study showed that in USA200, the most prominent class of genes
undergoing positive selection were those encoding cell envelope components (a third of all
genes with elevated dN/dS)186,190. An independent study verified that all of the metabolic
genes in USA300 exhibiting forward selection were completely conserved among 10
sequenced USA300 genomes43. Moreover, data from this same study showed that, while
relatively few SNPs were found among ten different USA300 genomes, genes encoding cell
envelope proteins more commonly exhibited high dN/dS ratios (57% of all genes with
multiple nonsynonymous substitutions)43. Thus, the peculiar overrepresentation of S. aureus
metabolic genes among those undergoing positive selection is only evident when comparing
USA300 with non-USA300 genomes implying that USA300 clones in general seem to be
adapting to disproportionately high selective pressures at the metabolic level.
It is possible that the resulting adaptive mutations in the overall metabolism of USA300
directly contribute to the evolutionary success of this clone. For instance, it has been
observed that USA300 clones simply grow faster than any other tested S. aureus isolate174.
Taken together, it would appear that USA300 is more metabolically fit and/or adaptable than
other S. aureus lineages. This may provide an advantage when competing for limiting
nutrients with endogenous microflora as well as contribute to severe disease given a rapid
growth rate within sterile sites of the body. Further inspection in our laboratory revealed that
USA300 clones have growth advantages when metabolizing many different carbon sources
(Table 1). In general, USA300 clones exhibited higher growth rates than other clones when
cultivated on nutrients that are abundant in human sweat and skin191, consistent with the
high prevalence of skin/soft tissue infections associated with USA300 clones. But, can a
relatively small set of amino acid changes in metabolic genes really account for such drastic
growth differences? Laboratory adaptation of E. coli to growth on lactate resulted in strains
that exhibited nearly twice the growth rate on lactate alone192. These adapted strains
exhibited major alterations in metabolic flux capacity through gluconeogenic and pyruvate
catabolic pathways, yet none of these changes were due to altered gene expression. This
would be consistent with subtle changes in protein sequence (nonsynonymous SNPs) that
alter enzyme activity or response to allosteric regulation. Furthermore, a laboratory adapted
clone of Caulobacter crescentus exhibited a ~20% greater growth rate than its progenitor
strain and this entire phenotype was explained by a single SNP altering the expression of
glucose-6-phosphate dehydrogenase (zwf)193. This enzyme controls the primary flux
between energy generating glycolysis and the precursor generating pentose-phosphate
pathway (PPP). It was shown that lower flux through PPP with concomitant increased
glycolytic activity lead to higher growth rates in lab-adapted C. crescentus193. Interestingly,
one of the very genes exhibiting signs of positive selection in USA300 was zwf along with
two glycolytic genes (pgm and pfkA) potentially linked to the USA300 growth advantage on
numerous carbon sources190. Whether or not SNPs within these metabolic genes account for
enhanced USA300 growth rates and whether that contributes to the success of this clone
remain to be proven, however the unusual SNP distribution among metabolic genes in
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USA300 combined with its enhanced growth rate suggest there may be more to USA300
virulence than newly acquired or overexpression of virulence genes.
Conclusions
The overwhelming success of USA300 in North America as the dominant source of CA-
MRSA infections represents a fascinating example of a pathogenic variant emerging as a
new threat to human health. The adaptations acquired by USA300 clones in the form of
novel genetic components, altered gene regulation and sequence polymorphisms likely act in
concert to provide these strains with a selective advantage. It appears as though USA300
hypervirulence, as assayed in animal models of infection, correlates with increases in
virulence gene expression and is apparent in HA-MRSA progenitors as well as other
unrelated CA-MRSA lineages. Whether this is due to hyperactive Agr resulting in elevated
PSM production and Sae expression (which in turn could lead to excess Hla and other
exoprotein excretion) remains to be proven. In contrast to overt virulence, traits that affect
transmission and colonization efficiency are inherently difficult to model in the laboratory. It
may prove, however that this aspect of USA300 biology is as critical to its success as is high
virulence potential. It remains to be determined whether newly acquired genetic components
(e.g. ACME) and/or sequence polymorphisms contribute to the rapid transmission and
success of USA300 in the community. In the end, we may appreciate that none of the three
evolutionary events (gene acquisitions, altered gene regulation, protein sequence
divergence) outlined here can alone explain the success of USA 300. Rather, the
amalgamation of all these events created the highly successful pathogen that we must
contend with today.
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Figure 1. Schematic representation of the evolution of MRSA
Sequence Types (STs) belonging to established Clonal Complexes (CCs) are colored as
follows: CC1, purple; CC5, green; CC8, red; CC22, orange; CC30, blue; CC45, black. ST59
has not been assigned to a CC. Roman numerals reflect acquired SCCmec type. Commonly
used S. aureus strains are depicted around their relevant ST symbol.
Thurlow et al. Page 25






















Figure 2. Association between arc gene cluster and speG in ACME. TOP
ACME type I, found in USA300 S. aureus and also found in many S. epidermidis isolates,
and ACME type II, found primarily in S. epidermidis, both harbor arc gene clusters as well
as speG. ACME type III (not shown) lacks an identifiable arc gene cluster but does contain
an opp-3 locus. BOTTOM: Fate of host arginine depends on competition between iNOS
and Arginase-1 enzyme activities. The net production of ornithine by Arc-expressing S.
aureus may skew the fate of host arginine down the polyamine synthesis pathway thereby
necessitating speG.
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